TMCnet News
Research and Markets: The Pharmaceutical Market: Sweden 2015Research and Markets (http://www.researchandmarkets.com/research/9dtc3q/the) has announced the addition of the "The Pharmaceutical Market: Sweden" report to their offering. We remain of the opinion that Sweden's overall pharmaceutical market value will decline over the forecast period to 2016, both in local currency and US dollar terms. We base our view on patent expiration and cost containment policies , which will continue to stimulate consumption of cheaper generic medicines. Moreover, in the short term, weak consumer confidence in Sweden may affect the growth of its non-prescription market , while - in the longer-term - we expect a drop in consumers' willingness to consume non-reimbursed medicines Headline Expenditure Projections: Pharmaceuticals: SEK42.84bn (US$6.60bn) in 2011 to SEK42.17bn (US$6.12bn) in 2012; -1.6% in local currency terms and -7.2% in US dollar terms. Forecasts broadly in line with previous quarter. Healthcare: SEK327.00bn (US$50.36bn) in 2011 to SEK336.36bn (US$48.82bn) in 2012; +2.9% in local currency terms and -3.1% in US dollar terms. Forecasts broadly in line with previous quarter. Medical devices: SEK21.04bn (US$3.24bn) in 2011 to SEK21.86bn (US$3.17bn) in 2012; +3.9% in local currency terms and -2.1% in US dollar terms. Forecasts broadly in line with previous quarter. Competitive Landscape: The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Company Profiles - AstraZeneca - GlaxoSmithKline - Meda - Medivir - Merck & Co - Novartis - Pfizer - Sanofi - Swedish Orp For more information visit http://www.researchandmarkets.com/research/9dtc3q/the
View source version on businesswire.com: http://www.businesswire.com/news/home/20150522005535/en/ |
